Blood management and radical retropubic prostatectomy: Quebec experience

One of the concerns of patients undergoing radical retropubic prostatectomy (RRP) is the risk of intraoperative bleeding and the subsequent need of blood products. Patients can presently consider pre-operative autologuous blood donation (PAD) prior to elective urological oncology surgery to decrease the risk of allogenic transfusion. We reviewed the medical charts of 141 patients that had a RRP in the CHUQ-Pavillon H?tel-Dieu de Québec in 1996 for prostate cancer. The average and median blood loss were respectively 804 cc and 650 cc, but more than 75% of patients lost less than 1,000 ml. Allogeneic transfusion was required in 11 (7.8%) patients. PAD was done in 45.4 %. The clinical characteristics of patients with PAD were similar to the patients who did not bank blood. The need for allogeneic transfusion was reduced to 3% (2/64) in the patients with PAD compared to 11.7% for the 77 patients without PAD. The average blood loss was higher in the 11 patients that received allogenic blood (1641 cc vs 734 cc, p < 0.01), but their average preoperative Hb was lower (127.9 vs 141.9, p < 0.01). These results suggest that there may be other effective methods in preventing the need for allogenic blood transfusion in RRP.     

Molecular findings and clinical data in a cohort of 150 patients with anophthalmia/microphthalmia

Anophthalmia and microphthalmia (AM) are the most severe malformations of the eye, corresponding respectively to reduced size or absent ocular globe. Wide genetic heterogeneity has been reported and different genes have been demonstrated to be causative of syndromic and non‐syndromic forms of AM. We screened seven AM genes [GDF6 (growth differentiation factor 6), FOXE3 (forkhead box E3), OTX2 (orthodenticle protein homolog 2), PAX6 (paired box 6), RAX (retina and anterior neural fold homeobox), SOX2 (SRY sex determining region Y‐box 2), and VSX2 (visual system homeobox 2 gene)] in a cohort of 150 patients with isolated or syndromic AM. The causative genetic defect was identified in 21% of the patients (32/150). Point mutations were identified by direct sequencing of these genes in 25 patients (13 in SOX2, 4 in RAX, 3 in OTX2, 2 in FOXE3, 1 in VSX2, 1 in PAX6, and 1 in GDF6). In addition eight gene deletions (five SOX2, two OTX2 and one RAX) were identified using a semi‐quantitative multiplex polymerase chain reaction (PCR) [quantitative multiplex PCR amplification of short fluorescent fragments (QMPSF)]. The causative genetic defect was identified in 21% of the patients. This result contributes to our knowledge of the molecular basis of AM, and will facilitate accurate genetic counselling.     

Phosphoinositide substrates of myotubularin affect voltage-activated Ca2+ release in skeletal muscle

Skeletal muscle excitation–contraction (E–C) coupling is altered in several models of phosphatidylinositol phosphate (PtdInsP) phosphatase deficiency and ryanodine receptor activity measured in vitro was reported to be affected by certain PtdInsPs, thus prompting investigation of the physiological role of PtdInsPs in E–C coupling. We measured intracellular Ca²⁺ transients in voltage-clamped mouse muscle fibres microinjected with a solution containing a PtdInsP substrate (PtdIns(3,5)P ₂ or PtdIns(3)P) or product (PtdIns(5)P or PtdIns) of the myotubularin phosphatase MTM1. No significant change was observed in the presence of either PtdIns(5)P or PtdIns but peak SR Ca²⁺ release was depressed by ~30% and 50% in fibres injected with PtdIns(3,5)P ₂ and PtdIns(3)P, respectively, with no concurrent alteration in the membrane current signals associated with the DHPR function as well as in the voltage dependence of Ca²⁺ release inactivation. In permeabilized muscle fibres, the frequency of spontaneous Ca²⁺ release events was depressed in the presence of the three tested phosphorylated forms of PtdInsP with PtdIns(3,5)P ₂ being the most effective, leading to an almost complete disappearance of Ca²⁺ release events. Results support the possibility that pathological accumulation of MTM1 substrates may acutely depress ryanodine receptor-mediated Ca²⁺ release. Overexpression of a mCherry-tagged form of MTM1 in muscle fibres revealed a striated pattern consistent with the triadic area. Ca²⁺ release remained although unaffected by MTM1 overexpression and was also unaffected by the PtdIns-3-kinase inhibitor LY2940002, suggesting that the 3-phosphorylated PtdIns lipids active on voltage-activated Ca²⁺ release are inherently maintained at a low level, inefficient on Ca²⁺ release in normal conditions.